Forty Seven

Forty Seven was a clinical-stage immuno-oncology company that pioneered the development of therapies targeting the CD47 pathway, a critical "don't eat me" signal used by cancer cells to evade the immune system. The company's lead therapeutic candidate, magrolimab, is a monoclonal antibody designed to block CD47 and stimulate macrophages to engulf and eliminate tumor cells. Founded by world-renowned researchers from Stanford University, Forty Seven established a leading position in macrophage checkpoint inhibition. Their pipeline included several novel antibodies aimed at treating hematological malignancies and solid tumors. In April 2020, the company was acquired by Gilead Sciences for approximately $4.9 billion, integrating its innovative programs into Gilead's expanding oncology portfolio.